#1 Clinical Trials Search in Europe

Remibrutinib

Remibrutinib is an investigational drug currently being studied in clinical trials for several medical conditions. This article provides an overview of the ongoing research into remibrutinib’s potential uses, efficacy, and safety across different diseases. Clinical trials are evaluating remibrutinib for conditions like chronic spontaneous urticaria, multiple sclerosis, myasthenia gravis, and more.

Table of Contents

What is Remibrutinib?

Remibrutinib, also known as LOU064, is a new medication being developed to treat various conditions[1][2]. It belongs to a class of drugs called Bruton’s tyrosine kinase (BTK) inhibitors. BTK inhibitors work by blocking a specific protein in the body that plays a role in certain immune system responses and inflammation[5].

Conditions Treated by Remibrutinib

Remibrutinib is being studied for the treatment of several conditions, including:

  • Chronic Spontaneous Urticaria (CSU): This is a skin condition characterized by recurring hives and itching that last for more than six weeks without an apparent trigger[1][6].
  • Chronic Inducible Urticaria (CINDU): This condition involves hives that are triggered by specific stimuli such as heat, cold, or pressure[2].
  • Relapsing Multiple Sclerosis (RMS): A neurological condition where the immune system attacks the protective covering of nerves in the brain and spinal cord[4][5].
  • Sjögren’s Syndrome: An autoimmune disorder that primarily affects the tear and salivary glands, causing dry eyes and mouth[5].
  • Peanut Allergy: A severe allergic reaction to peanuts that can be life-threatening[3].

How Remibrutinib Works

Remibrutinib works by targeting and inhibiting a specific enzyme in the body called Bruton’s tyrosine kinase (BTK). This enzyme plays a crucial role in the activation and function of certain immune cells. By blocking BTK, remibrutinib can help reduce inflammation and abnormal immune responses that contribute to various conditions[5].

In conditions like chronic urticaria, remibrutinib may help reduce the frequency and severity of hives and itching. For multiple sclerosis, it may help slow down the progression of the disease and reduce the frequency of relapses. In Sjögren’s syndrome, it may help alleviate symptoms by reducing inflammation in the affected glands[1][2][4][5].

How Remibrutinib is Administered

Remibrutinib is typically taken orally in the form of tablets or capsules. The dosage and frequency of administration may vary depending on the condition being treated and the specific clinical trial. Some common dosing regimens being studied include:

  • 25 mg twice daily for chronic urticaria[6]
  • 100 mg once or twice daily for Sjögren’s syndrome[5]
  • Various doses for multiple sclerosis, to be determined based on ongoing studies[4][5]

It’s important to note that as remibrutinib is still in clinical trials, the optimal dosing for each condition is still being determined[1][2][3][4][5][6].

Current Clinical Trials

Remibrutinib is currently being studied in several clinical trials for different conditions:

  • Chronic Spontaneous Urticaria: Phase 3 trials are comparing remibrutinib to placebo and to omalizumab (another medication used for CSU)[1][6].
  • Chronic Inducible Urticaria: A Phase 3 trial is evaluating remibrutinib’s effectiveness in various types of CINDU, including cold urticaria and cholinergic urticaria[2].
  • Relapsing Multiple Sclerosis: Two identical Phase 3 trials are comparing remibrutinib to teriflunomide, an existing MS treatment[4][5].
  • Sjögren’s Syndrome: A Phase 2 study has been completed to evaluate the safety and efficacy of remibrutinib in patients with moderate to severe Sjögren’s syndrome[5].
  • Peanut Allergy: A Phase 2 study is investigating whether remibrutinib can increase the amount of peanut protein that patients can tolerate without an allergic reaction[3].

These trials are designed to assess the effectiveness, safety, and optimal dosing of remibrutinib for each condition[1][2][3][4][5][6].

Potential Side Effects

As remibrutinib is still in clinical trials, the full range of potential side effects is not yet known. However, researchers are closely monitoring participants for any adverse events. Common side effects observed in clinical trials may include:

  • Headache
  • Nausea
  • Fatigue
  • Upper respiratory tract infections

More serious side effects are being carefully evaluated in the ongoing clinical trials. It’s important to note that the safety profile of remibrutinib may vary depending on the condition being treated and the dosage used[1][2][3][4][5][6].

Condition Trial Phase Key Outcomes Measured Dosing
Chronic Spontaneous Urticaria Phase 3b Change in UAS7 score, itch severity, hives severity 25 mg twice daily
Relapsing Multiple Sclerosis Phase 3 Annualized relapse rate, disability progression Compared to teriflunomide
Generalized Myasthenia Gravis Phase 3 Change in MG-ADL and QMG scores Not specified
Chronic Inducible Urticaria Phase 3 Response in symptom scores for different CINDU subtypes Not specified
Sjögren’s Syndrome Phase 2 Change in ESSDAI score, fatigue, quality of life 100 mg once or twice daily
Peanut Allergy Phase 2 Tolerance to peanut protein during oral food challenge Not specified

FAQ

  • What is remibrutinib? Remibrutinib is an investigational drug that is being studied as a potential treatment for several medical conditions. It is a Bruton's tyrosine kinase (BTK) inhibitor that is taken orally.
  • What conditions is remibrutinib being studied for? Based on the clinical trials data, remibrutinib is being investigated for chronic spontaneous urticaria, relapsing multiple sclerosis, generalized myasthenia gravis, chronic inducible urticaria, Sjögren's syndrome, and peanut allergy.
  • How is remibrutinib administered? Remibrutinib is typically administered as an oral tablet. The dosage and frequency vary depending on the condition being studied, but common regimens include 25 mg twice daily or 100 mg once or twice daily.
  • What are some of the potential benefits being studied? Clinical trials are evaluating remibrutinib's potential to reduce disease activity, improve symptoms, and enhance quality of life in various conditions. For example, in chronic spontaneous urticaria, it's being studied for its ability to reduce itch and hives. In multiple sclerosis, it's being evaluated for reducing relapses and disability progression.
  • Are there any known side effects of remibrutinib? As with any investigational drug, the full safety profile of remibrutinib is still being determined through clinical trials. The studies are monitoring for adverse events and serious adverse events. Specific side effects may vary depending on the condition being treated and will be better understood as more trial data becomes available.

Ongoing Clinical Trials on Remibrutinib

  • Remibrutinib in Chronic Spontaneous Urticaria for Patients Who Benefited from a Previous Remibrutinib Trial

    Recruiting

    3 1 1
    Investigated drugs:
    Bulgaria Czechia France Germany Poland Spain

  • A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

    Recruiting

    3 1
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study comparing remibrutinib and ocrelizumab in patients with relapsing multiple sclerosis who switch from ocrelizumab treatment

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Czechia Denmark France Germany Greece +4

  • Evaluation of remibrutinib (LOU064) effectiveness and safety in adult patients with chronic urticaria: A 12-week placebo-controlled study

    Recruiting

    2 1 1
    Investigated drugs:
    France Germany Poland Spain

  • Study on the Effects of Remibrutinib for Patients with Generalized Myasthenia Gravis

    Recruiting

    3 1
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Poland +2

  • Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

    Not yet recruiting

    3 1
    Investigated drugs:
    Belgium Bulgaria Czechia France Germany Greece +6

  • Study on the Effects of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    3 1 1
    Investigated drugs:
    Bulgaria Denmark Germany Greece Italy Poland +3

  • Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

    Not recruiting

    3 1 1
    Investigated drugs:
    Bulgaria Croatia Czechia Estonia France Germany +9

  • Study on the Effectiveness and Safety of Remibrutinib for Adults with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +4

  • Study of remibrutinib for long-term treatment of adult patients with chronic spontaneous urticaria who completed previous remibrutinib studies

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Denmark France Germany Hungary +4

Glossary

  • Remibrutinib: An investigational oral medication that inhibits Bruton's tyrosine kinase (BTK), being studied for various autoimmune and inflammatory conditions.
  • Chronic Spontaneous Urticaria (CSU): A condition characterized by the spontaneous appearance of itchy hives, wheals, and/or angioedema that last for more than 6 weeks without an identifiable external trigger.
  • Relapsing Multiple Sclerosis (RMS): A form of multiple sclerosis characterized by clearly defined attacks of new or increasing neurologic symptoms followed by periods of partial or complete recovery.
  • Generalized Myasthenia Gravis: An autoimmune neuromuscular disorder causing muscle weakness and fatigue, affecting multiple muscle groups throughout the body.
  • Sjögren's Syndrome: An autoimmune disorder that primarily affects the tear and salivary glands, causing dry eyes and dry mouth, but can also affect other parts of the body.
  • EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI): A clinical index used to measure disease activity in patients with Sjögren's Syndrome, evaluating 12 organ-specific domains.
  • Urticaria Activity Score (UAS7): A patient-reported outcome measure used to assess disease activity in chronic spontaneous urticaria, combining weekly itch severity and hive count scores.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and excreted by the body, including measurements like maximum concentration (Cmax) and area under the curve (AUC).
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare against the effects of the investigational drug.

References